

# 1     **CONCENTRATED EMULSION FORMULATION FOR SILATECAN**


## 2     BACKGROUND OF THE INVENTION

### 3     1. Field of the Invention

4             The present invention relates to a concentrated emulsion formulation,  
5     and particularly to a waterless emulsion formulation for water-insoluble  
6     silatecan.

### 7     2. Description of Related Art

8             Silatecan (7-t-butyldimethylsilyl-10-hydroxycamptothecin, DB-67) is  
9     known to be an inhibitor of topoisomerase, which suppresses tumor cells and  
10    also has extremely low water-solubility. Thus, particularly selected solvents  
11    must be used for preparation of an injectable silatecan dose. The chemical  
12    structure of the silatecan is shown as follows:



13  
14  
15             Pharmaceutical compounds are classified into two groups – the  
16    water-soluble and the water-insoluble groups. Medicine containing water-  
17    soluble compounds is prepared relatively easier. Taking the antitussive

1 "dextromethorphen" as an example, dextromethorphen is easily dissolved in  
2 water and thus has been prepared in a variety of pharmaceutical dosage forms,  
3 such as tablets, solutions, syrups etc. Another example is the anti-cancer drug  
4 "doxorubicin," which has excellent solubility in water and is easily formulated  
5 into an aqueous solution for injection. On the contrary, the manufacturing  
6 process of medicine containing water-insoluble effective compounds is  
7 usually difficult and complex. For example, the anti-cancer medicine  
8 "paclitaxel" underwent a difficult development period before marketing. Then,  
9 serious allergic reactions were observed in Phase I of clinical trials of the drug,  
10 which almost led to termination of the clinical trials. The allergic reactions  
11 included suffocating, hypotension, angioedema, systemic urticaria, all of which  
12 were similar to the negative reactions associated with contrasting agents for  
13 angiography. By using multiple drugs for prevention and modifying the rate of  
14 injection, the allergic reactions caused by paclitaxel were reduced finally. The  
15 reason for those allergic reactions was found to be primarily associated with  
16 the solvents used in the preparing process of paclitaxel rather than paclitaxel  
17 itself.

18 Paclitaxel is very difficult to dissolve in water (less than 1 µg/mL).  
19 Therefore, solvents suitable for preparing a medicament containing paclitaxel  
20 must be investigated. This is an obstacle for manufacturing paclitaxel-  
21 containing medicine. The only solvent that was disclosed by Squibb U.S. is  
22 used for intravenous doses of paclitaxel, composing of ethanol and Cremophor  
23 EL (polyoxyethylated castor oil) in a ratio of 50:50. However, Cremophor EL  
24 is so toxic that it causes serious allergic reactions, even fatal, after injection.

1 Obviously, the injectable paclitaxel medicine resulted in the allergic  
2 reactions just because of use of Cremophor EL. Therefore, the drawbacks of  
3 the paclitaxel-containing medicine can be eliminated by replacing Cremophor  
4 EL with any other less toxic solvent. Nonetheless, a suitable solvent for  
5 manufacturing paclitaxel-containing medicine should not only render the  
6 manipulation of the insoluble drug much easier but also provide sufficient  
7 safety as a medicament.

8 To improve the injection dosage containing paclitaxel compound with  
9 low water solubility, the injection dosage was made in the form of liposome.  
10 However, the paclitaxel compound in liposome for injection dosage was found  
11 to become deposited within several weeks of its shelf life. Therefore, the  
12 liposomes were frozen into powder to avoid the deposition of the paclitaxel  
13 compound during storage. However, the processes of making the liposomes  
14 were complex, and freezing processes are time-consuming with high  
15 operational costs, which make the paclitaxel medicine high in production cost  
16 and disadvantageous commercially. Other modifications of paclitaxel  
17 medicine but having easier manufacturing processes were disclosed. For  
18 example, some organic solvents such as dimethylacetamide (DMA) and N-  
19 methylpyrrolidinone (NMP) were used to substitute the Cremophor EL to  
20 increase the solubility of the paclitaxel compound. However, although the  
21 aforementioned organic solvents did simplify the manufacturing processes  
22 they still had certain toxicity. Therefore, the organic solvents are not widely  
23 accepted by pharmaceutical manufacturers.

24 Another special method was to mix the paclitaxel compound with

1 other non-toxic materials such as using plasma protein to absorb paclitaxel to  
2 obtain non-toxic and water-insoluble paclitaxel medicine of an injectable  
3 dosage.

4 Compounds having low water-solubility such as paclitaxel were  
5 usually prepared into an emulsion to overcome the solubility problem to make  
6 the paclitaxel distributed evenly. Emulsifying the paclitaxel was more  
7 complex than using the specific solvents to dissolve the paclitaxel, and thus  
8 had a high manufacturing cost. Additionally, the emulsifier used in the  
9 emulsifying processes usually contained water that makes the paclitaxel have  
10 a poor stability during long-period storage. Meanwhile, the paclitaxel became  
11 deposited easily and crystallized in the emulsion form in the same way as in  
12 the liposome form.

13 According to the above description, methods for preparing medicine  
14 containing water-insoluble compounds comprised using organic solvents,  
15 using surfactant, and using specific carrying media (such as liposome) to  
16 achieve the purpose of evenly dispersing the water-insoluble compounds in  
17 the medicine in different dosage forms. However, these methods all had  
18 problems of excessive toxicity caused from solvents, quality control  
19 difficulties due to complex processing etc.

20 The present invention has arisen to mitigate or obviate the  
21 disadvantages of the conventional method for preparing medicine containing  
22 water-insoluble compounds, especially silatecan.

## 23 SUMMARY OF THE INVENTION

24 The first objective of the present invention is to provide an emulsion

1 formulation for silatecan, which contains no toxic excipient and enables other  
2 water-insoluble compounds to be applied to reduce side effects of the obtained  
3 medicine. Wherein, the objective is achieved by the following emulsion  
4 formulation:

5 phospholipid of 4.79-75 %(W/W);  
6 propylene glycol of 24.79~95 %(W/W);  
7 optional ethanol of 0.1-40 %(W/W);  
8 optional surfactant of 0.1-10 %(W/W), especially Tween<sup>®</sup> 80; and  
9 silatecan of 0.01-1.0 %(W/W).

10 The second objective of the present invention is to provide an  
11 emulsion formulation for silatecan, wherein manufacturing processes of the  
12 emulsion formulation are simply to reduce the production cost of the silatecan  
13 medicine.

14 Further benefits and advantages of the present invention will become  
15 apparent after a careful reading of the detailed description.


#### 16 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

17 A concentrated emulsion formulation for silatecan or other water-  
18 insoluble compounds, the emulsion formulation comprising:

19 phospholipid of 4.79-75 %(W/W);  
20 propylene glycol of 24.79~95 %(W/W);  
21 optional ethanol of 0.1-40 %(W/W);  
22 optional surfactant of 0.1-10 %(W/W), especially Tween<sup>®</sup> 80 and  
23 silatecan of 0.01-1.0 %(W/W).

24 The emulsion formulation in the present invention uses non-toxic

1 organic solvents and optional surfactants to dissolve waterless and water-  
 2 insoluble compounds. The phospholipid is preferred to be phospholipon<sup>®</sup>90G,  
 3 which contains a minimum 90% phosphatidylcholine for the manufacture of  
 4 liposomes. The phosphatidylcholine is shown in following chemical structure:



5  $\text{R}_1, \text{R}_2 = \text{Fatty Acid Residues}$  --- (L- $\alpha$ -Phosphatidylcholine)

6 The organic solvents and surfactants are propylene glycol, optional  
 7 ethanol and optional Tween<sup>®</sup>80 (or polysorbate 80, purchased from Fisher  
 8 Scientific) and are simultaneously mixed with phospholipon<sup>®</sup>90G in a mixer  
 9 without the need for any extra equipment to achieve a pharmaceutically  
 10 acceptable emulsion. Therefore, the emulsion for silatecan or other water-  
 11 insoluble compounds has a low manufacturing cost.

12 Additionally, the emulsion formulation contains no water and thus has  
 13 an excellent stability such that the emulsion formulation can be preserved for a  
 14 long time, at least two years at room temperature. Since the emulsion is  
 15 obtained in a dense situation, the emulsion has to be diluted before  
 16 administration. Take an intravenous injection for example, the emulsion is  
 17 diluted with a suitable diluent for the intravenous injection such as an aqueous  
 18 solution, oily solvent or lipid diluent. The aqueous solution is selected from

1 the group consisting of injection water, glucose solution, saline, Ringer's  
2 solution and other injection solutions. The oily solvents are selected from the  
3 group consisting of triglycerides, propylene glycol diesters and other mixtures,  
4 wherein the triglycerides contain 9-83 carbon atoms and the propylene glycol  
5 diesters contain 15-60 carbon atoms. The lipid diluent is selected from the  
6 group consisting of commercially-available products such as  
7 Liposyn<sup>®</sup>(purchased from Abbott Laboratories), Soyacal<sup>®</sup>(purchased from  
8 GRIFOLS), Travemulsion<sup>®</sup>, Intralipid<sup>®</sup>(purchased from Fresenius Kabi) etc.  
9 Wherein, Liposyn<sup>®</sup> is composed of safflower oil, soybean oil, 1.2% egg  
10 phosphatides added as an emulsifier and glycerin in water. Wherein, Soyacal<sup>®</sup>  
11 is a synthetic lipid emulsion, Travemulsion<sup>®</sup> is a lipid emulsion and Intralipid<sup>®</sup>  
12 is an egg lecithin.

13 After diluting, the diluted emulsion remains stable and the water-  
14 insoluble compound does not decompose or crystallize to a deposit within 24  
15 hours. In fact, if the water-insoluble compounds are sensitive to light, the  
16 emulsion provides a photo-resisting efficiency to make the water-insoluble  
17 compounds stable and safe.

18 Silatecan is the main subject studied in the present invention but other  
19 water-insoluble compounds are also applicable in the emulsion formulation.

20 Without intending to limit in any manner, the present invention is further  
21 illustrated by the following examples.

22 Example 1: concentrated emulsion formulation containing 3mg/mL silatecan

23 Ingredient of the emulsion formulation is listed on table 1.

24 Table 1: ingredient of 3mg/mL silatecan concentrated emulsion

Compound	Quantity
Silatecan (DB67)	0.31g
Phospholipon 90G	34.9g
Propylene glycol	52.9g
Ethanol q.s.(quantum sufficit)	14.0mL

1 Silatecan, phospholipon, propylene glycol, and ethanol were  
2 simultaneously mixed together, heated in a water-bath at 70-80°C, and then  
3 stirred by a magnet for 2 hours to obtain 3 mg/mL waterless emulsion of  
4 silatecan. The silatecan emulsion was divided into 4 parts to be individually  
5 stored at 5°C ± 2°C, 25°C ± 2°C, 30°C ± 2°C, 40°C ± 2°C. All parts of the  
6 silatecan emulsion were tested for concentration variation and had no obvious  
7 deposition or decomposition within 6 months, as shown in Table 2.

8 Table 2: stability test for 3mg/mL silatecan concentrated emulsion

Storage period	Concentration mg/mL			
	5°C ± 2°C	25°C ± 2°C	30°C ± 2°C	40°C ± 2°C
0	3.04 ± 0.18	3.04 ± 0.18	3.04 ± 0.18	3.04 ± 0.18
1 <sup>st</sup> month	3.11 ± 0.22	3.12 ± 0.13	3.18 ± 0.21	3.10 ± 0.24
2 <sup>nd</sup> month	2.98 ± 0.11	3.02 ± 0.17	3.05 ± 0.19	3.12 ± 0.19
3 <sup>rd</sup> month	3.12 ± 0.28	2.09 ± 0.18	3.12 ± 0.22	3.08 ± 0.26
6 <sup>th</sup> month	2.97 ± 0.15	3.18 ± 0.22	2.95 ± 0.23	3.11 ± 0.15

9 A 3.5mL sample of 3mg/mL silatecan concentrated emulsion was  
10 diluted with 100mL of 5% dextrose solution or intravenous injecting water  
11 and stirred for 1 minute to obtain a homogeneous liquid solution. To study the  
12 stability and crystallization of the silatecan concentrated emulsion after

diluting, the liquid solution was filtered with a membrane of 0.45µm pores and then the filtered liquid solution was tested for concentration variation to determine the crystallizing ratio. The stability test was held at the beginning, 4<sup>th</sup> hour, 8<sup>th</sup> hour, 12<sup>th</sup> hour, and 24<sup>th</sup> hour after diluting (shown in Table 3).

Table 3: stability test for diluted silatecan emulsion after diluting.

Storage period	Concentration mg/mL*	
	Before filtering	After filtering
0	0.11± 0.01	0.10± 0.02
4 <sup>th</sup> hour	0.13± 0.01	0.11± 0.03
8 <sup>th</sup> hour	0.11± 0.02	0.10± 0.03
12 <sup>th</sup> hour	0.10± 0.02	0.12± 0.01
24 <sup>th</sup> hour	0.12± 0.01	0.13± 0.02

\*tested with HPLC

Example 2: concentrated emulsion formulation containing 6mg/mL silatecan

The ingredients of the emulsion formulation are listed in Table 4, which further contain 1% Tween<sup>®</sup>80 to diminish the amount of droplets of the emulsion to half the size of the droplets in example 1 and to condense the silatecan concentrated emulsion to 6mg/mL.

Table 4: ingredient of 6mg/mL silatecan concentrated emulsion

Compound	Quantity
Silatecan (DB67)	0.61g
Phospholipon 90G	34.5g
Propylene glycol	52.4g

Tween <sup>®</sup> 80	1.0 mL
Ethanol q.s.(quantum sufficit)	14.0mL

1 Silatecan, phospholipon, propylene glycol, Tween<sup>®</sup>80 and ethanol  
2 were simultaneously mixed together, heated in a water-bath at 70-80°C, and  
3 then stirred by a magnet for 2 hours to obtain 6 mg/mL waterless emulsion of  
4 silatecan. The silatecan emulsion was divided into 4 parts to be individually  
5 stored at 5°C ± 2°C, 25°C ± 2°C, 30°C ± 2°C, 40°C ± 2°C. All parts of the  
6 silatecan emulsion were tested for concentration variation and had no obvious  
7 deposition or decomposition within 6 months as shown in Table 5.

8 Table 5: stability test for 6mg/mL silatecan concentrated emulsion

Storage period	Concentration mg/mL			
	5°C ± 2°C	25°C ± 2°C	30°C ± 2°C	40°C ± 2°C
0	6.01± 0.20	6.01± 0.20	6.01± 0.20	6.01± 0.20
1 <sup>st</sup> month	6.04± 0.23	5.97± 0.15	6.15± 0.11	6.04± 0.21
2 <sup>nd</sup> month	6.12± 0.18	6.15± 0.19	5.91± 0.18	6.03± 0.20
3 <sup>rd</sup> month	5.97± 0.22	5.96± 0.22	6.11± 0.14	5.91± 0.11
6 <sup>th</sup> month	6.17± 0.23	6.05± 0.14	5.90± 0.21	6.01± 0.14

9 A 9.0 mL sample of 6mg/mL silatecan concentrated emulsion was  
10 diluted with 100mL of 5% dextrose solution or intravenous injecting water  
11 and stirred for 1 minute to obtain a homogeneous liquid solution. To study the  
12 stability and crystallization of the silatecan concentrated emulsion after  
13 diluting, the liquid solution was filtered with a membrane of 0.45µm pores and  
14 then the filtered liquid solution was tested for concentration variation to  
15 determine the crystallizing ratio. The stability test was held at the beginning,

1 4<sup>th</sup> hour, 8<sup>th</sup> hour, 12<sup>th</sup> hour, and 24<sup>th</sup> hour after diluting (shown in Table 6).

2 Table 6: stability test for diluted silatecan emulsion after diluting.

Storage period	Concentration mg/mL*	
	Before filtering	After filtering
0	0.50± 0.03	0.49± 0.01
4 <sup>th</sup> hour	0.49± 0.02	0.52± 0.02
8 <sup>th</sup> hour	0.55± 0.02	0.52± 0.03
12 <sup>th</sup> hour	0.47± 0.02	0.49± 0.04
24 <sup>th</sup> hour	0.50± 0.03	0.52± 0.02

3 \*tested with HPLC

4 The concentrated silatecan emulsion in the present invention was  
5 simply obtained by mixing multiple non-toxic solvents and a surfactant  
6 together to simplify the manufacturing process of water-insoluble compounds.  
7 Therefore, the concentrated silatecan emulsion is non-toxic and has a low  
8 manufacturing cost. Meanwhile, the concentrated silatecan emulsion is  
9 waterless to keep the silatecan stable in the emulsion and being waterless even  
10 keeps it stable for at least 24 hours after diluting.

11 Although the invention has been explained in relation to its preferred  
12 embodiment, many other possible modifications and variations can be made  
13 without departing from the spirit and scope of the invention as hereinafter  
14 claimed.